Conditions: Parkinson's Disease Dyskinesia
Keywords: Parkinson's Disease Dyskinesia Dyskinesia associated with dopaminergic treatment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 506
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Sarizotan intervention 2: Placebo
Intervention descriptions: intervention 1: Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks. intervention 2: Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.

Protocol document: